BP, use-dependent sodium channel blocker
Ph. II oral efficacy in trigeminal neuralgia
from cell-based HTS and ligand-based opt.
ACS Med. Chem. Lett., Jul. 16, 2020
biogen / Convergence / GSK, MA / UK
Vixotrigine (BIIB074)
1 min read
Vixotrigine (BIIB074) is a voltage-gated sodium channel blocker that preferentially binds to the inactivated state of the sodium channels, conferring selectivity for channels involved in pain-associated high frequency nerve signalling over normal low frequency nerve signalling (use-/state-dependence). The use-dependent activity is believed to confer a better safety window over previous generations of sodium channel inhibitors. Two Ph. III clinical trials appear to be planned for trigeminal neuralgia with estimated start dates in mid-2021.
Search By Structure
- GS-6207
- PF-06826647
- MSA-2
- SR-717
- Vixotrigine (BIIB074)
- BI-3406
- “compound 3d”
- “compound 12”
- “compound 12j”
- “compound 7f”
- DS34942424
- “compound 12”
- “compound 37”
- “compound 20”
Molecules of the Month
2023
2022
2021
2020